Midterm lectures 2-4 Flashcards
pathophysiology of T1DM
autoimmune destruction of beta cells
leads to insulin deficiency and hyperglycaemia
etiology is largely unknown but involves genetic predisposition, environmental components and distinctive metabolic changes
primary clinical systems are associated with acute hyperglycaemia and ketoacidosis
genetics and environment interact
autoantigens form on beta cells, activate T cells and you get Abs
-> can detect Abs before diabetes develops
how much beta cell function is left by the time you have symptoms of T1DM?
10%
2 Abs we can measure clinically for T1DM development
insulin and glutamic acid decarboxylase ( within islet cell)
can measure and predict likelihood of developing T1DM
how many Abs can be measured in research for T1DM development?
5
annual increase in incidence of T1DM in children
3.4%
annual incidence is 0.2% of children under 18
prevalence is 1 in 600 school children
does T2 or T1 have a greater genetic component?
T2 - about 50%
T1 only about 15% will have first degree relative with it
why is there an increase in T1 and T2 around puberty?
probably because at this time there is an increase in insulin resistance
criteria for diagnosis of T1DM
polyuria and polydipsia
glycosuria and ketonuria
random blood glucose > 11.1 mol/L
only need to do fasting plasma glucose if random was 6-7
don’t usually need to do OGTT or A1C
early presentation of T1DM
polydipsia
polyuria
weight loss
late presentation of T1DM
diabetic ketoacidosis vomiting dehydration abdominal pain hypovolemic shock hyperventilation due to acidosis drowsiness coma
what is DKA?
a life threatening complication due to insulin deficiency
insulin deficiency leads to increased counter regulating hormones - glucagon, cortisol, catecholamines and growth hormone
which then leads to increased lipolysis, ketogenesis and acidosis
causes decrease in pH of the blood which is what causes the morbidity or mortality (not the level of blood sugar)
what are the clinical manifestations of DKA?
dehydration
tachypnea (deep, singing (Kussmual) respiration)
nausea, vomiting and abdominal pain
confusion, drowsiness, progressive obtundation and loss of consciousness
diagnosis of DKA
blood glucose > 11 mmol/L
venous pH < 7.3 or bicarbonate < 15 mmol/L
ketonemia and ketonuria
what is a major concern with DKA in children?
increased risk of cerebral edema
(0.7-3% of cases)
have high morbidity (21-35%) and mortality (21-24%)
how to manage T1DM?
insulin administration
blood glucose monitoring
dietary counselling
education
what kind of education is needed after a child is diagnosed with T1DM?
prevention, detection and treatment of hypoglycemia insulin action and administration dosage adjustment blood glucose and ketone testing sick-day management prevention of DKA nutrition and exercise
what is blood sugar normally?
between 4 and 6 mmol/L
what is target A1C for ppl with T1DM? what is this equivalent to?
under 7% for children
equivalent to blood sugar of 8
(<7.5 for youths, <7.0 for adolescents)
7.0 for adults, 7.5 healthy older adults, 8 complex/intermediate, 8.5 very complex/poor health
what did DCCT show?
clearly demonstrated that intensive therapy and control of DM delayed the onset and slowed progression of complications
also showed “metabolic memory” - i.e. early control is better
long-term influence of early metabolic control on clinical outcomes
ie intensive group continued to have slower complications even after A1Cs converged
bolus insulin
the amount of insulin required to cover the food eaten
required to maintain euglycemia during absorption of a meal
basal insulin
small amount of insulin continuously released to cover the body’s non-food related insulin needs
required to maintain euglycemia during fasting and prevent excess formation of ketoacids
currently used rapid onset insulin
lispro and aspart
onset of action is 10-15 min
peak of action is 1-2 hours
duration of action is 3-5 hours
currently used slow onset insulin
detemir and glargine
onset is 2-3 hours
detemir has 6-8 hour peak
duration of action is 24 hours
describe rapid analog insulins
humalog, novorapid, apidra
rapid onset and short duration of action
reduced risk of hypoglycaemia
need to take 10-15 min before eating
increased dose does not increase duration of action
what are the target BG levels in T1DM patients?
4-7
describe basal analogue insulins
lantus, levemir, basiglar
prolonged action
onset about 2 hours, duration 22+/- 4 hours
no peak
rate of absorption at different sites doesn’t differ
not recommended to mix in a syringe with other insulins
basal-bolus insulin
4 shots a day
1 basal before bed, 3 bolus at each meal
this doesn’t include snack, only need bolus if more than 15 g carbs in a snack
basal is always the same (with pump you can change)
describe insulin pumps
basal rates are pre-programmed but can be varied
basal is infused 24/7 to cover the body’s non-food needs
burst of insulin used to meet requirements of food intake
used to correct high BG reading as entered by user
ie covers body’s food and correction needs
rapid-acting analogue insulin is in a cartridge and is delivered through a cannula implanted in subcutaneous tissue
need to change site every 3 days using a need
benefits of insulin pump therapy
modest improvement in A1C
reduces glucose variability
reduces hypoglycemia (nocturnal, exercise and assisted)
reduced insulin requirements
prevents “dawn phenomenon” - blood sugar increasing at 5am
improves quality of life bc it is more flexible, can sleep in, have snacks etc
requirements for a pump in london
BG testing 4 times daily
complete records
use abdomen
count carbs
communicate with team frequently and attend 3 or 4 a year
carry emergency supplies and wear medic alert
be able to work pump
financial - ontario gov pays, need to pay an extra 250 a month for supplies
what is glucose monitoring
- 4 times a day (before meals and at bedtime) plus occasional nocturnal values
- every 2-3 hours when sick
- whenever you have symptoms of hypoglycaemia
prick finger with BG meter
continuous glucose monitoring
glucose sensor is inserted into subcutaneous tissue and reads interstitial glucose (so about 20 min delay)
is attached to transmitter which sends values to pump
need to calibrate 3 times a day with meter glucose
facilitates glucose pattern recognition and alerts when out of range or expected to be
sensors last about a week
using sensor improves A1C (remember 1% A1C improvement can decrease complications by 40%)
what is the definition of hypoglycaemia?
development of autonomic or neuroglycopenic symptoms low BG (<4 mmol/L if on insulin) response to carb load
autonomic symptoms of hypoglycemia
trembling palpitations sweating anxiety hunger nausea
neuroglycopenic symptoms of hypoglycaemia
difficulty concentrating confusion weakness drowsiness vision changes difficulty speaking dizziness
mild hypoglycemia
autonomic, self treat
moderate hypoglycemia
autonomic and neuroglycopenic, self treat
severe hypoglycemia
autonomic and neuroglycopenic, need help, unconsciousness may occur
plasma glucose usually <2.8
steps to address hypoglycaemia
recognize symtoms and confirm by testing BG (<4) if possible
treat with 15g fast sugar
retest in 15 min and retreat if needed
then eat normal snack/meal at that time of day with 15g carbs plus protein
what is 15g of glucose?
tablets 3 packets sugar 3/4 of juice or soft drink 6 lifesavers tablespoon of honey
overall what are the goals of T1DM management?
normal growth and development normal home and school life good diabetic control through knowledge, technique and self-reliance avoidance of hypoglycemia prevention of long-term complications
what is unique about managing T1DM in children and adolescents?
physical and psychological growth and development
caloric and insulin requirements, target levels, education strategies change with age
going from parents treating to doing it yourself
needs to be flexible
diagnosis of T2DM
clinical criteria
- presentation can be similar to T1 i.e. polydipsia and polyuria, but usually isn’t acute i.e. occurs over months
- may be asymptomatic
- also look at demographics
biochemical criteria are the same as T1
RPG >11.1 or FPG >7.0
epidemiology of T2DM in children under 18
incidence in Canada is 1.54/100 000
but has important regional variation i.e. in manitoba was 12.45
clinical features of T2DM at diagnosis
1/3 asymptomatic
2/3 acanthosis nigrans - reflection on insulin resistance
95% obese
ketosis and DKA (used to think this was just T1)
PCOS - associated with insulin resistance
dyslipidemia, hypertension
liver and kidney involvement
i.e. sometimes already have complications at presentation if there was a long asymptomatic period
ethnicity of children with T2DM
44% were aboriginal
asian, hispanic are also more prone
8% of total diagnosed were under the age of 10